Michael Halstead News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AdvisorShares Investments LLC lowered its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 28.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 4,151 shares of the biopharmaceutical company’s stock after selling 1,621 shares during the period. AdvisorShares Investments LLC’s holdings in Intra-Cellular Therapies were worth $297,000 at the end of the […]

Sectoral Asset Management Inc. cut its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 94.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,420 shares of the biopharmaceutical company’s stock after selling 116,260 shares during the period. Sectoral Asset Management Inc.’s holdings […]

Mach 1 Financial Group LLC bought a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 7,180 shares of the biopharmaceutical company’s stock, valued at approximately $514,000. A number of […]

Several analysts have recently updated their ratings and price targets for Intra-Cellular Therapies (NASDAQ: ITCI): 4/24/2024 – Intra-Cellular Therapies had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $120.00 price target on the stock. 4/23/2024 – Intra-Cellular Therapies had its price target raised by analysts at Canaccord Genuity Group Inc. […]

Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 36.1% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 18,738 shares of the biopharmaceutical company’s stock after acquiring an additional 4,974 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s […]